Promoting Competition
and Investment in the
U.S. Life Sciences Ecosystem
The U.S. life sciences ecosystem depends on mergers and acquisitions (M&A) to bring together the resources, investment and expertise needed to develop and deliver treatments and cures for patients.
FUELING COMPETITION AND INNOVATION
M&A drives competition and investment across America's life sciences industry.
FACILITATING INNOVATION
Life sciences companies of all sizes engage in M&A to connect innovations with the resources needed to bring them to market.
DRIVING AMERICAN GROWTH, LEADERSHIP
M&A plays a critical role within America’s world-class life sciences industry.
U.S. biopharmaceutical companies headquartered in the U.S.
PARTNERS
ABOUT US
PULSE is a national coalition raising awareness about the unique and fundamental role of mergers and acquisitions (M&A) in America’s life sciences industry. M&A enables life sciences companies of all sizes to bring together resources, investment and expertise needed to develop and deliver new treatments and cures. PULSE members represent researchers, manufacturers and leaders of life sciences companies of all sizes that make up a diverse, vibrant life sciences industry across America.
LATEST NEWS
2H 2025 Highlights – Partnership for the U.S. Life Science Ecosystem (PULSE)
This year, life sciences mergers and acquisitions (M&A) played a crucial role in driving innovation and supporting America’s global leadership in the life sciences.
Rebounding Life Sciences M&A Signals Strength for Innovation
Following a challenging funding and policy environment, new data shows an uptick in biopharmaceutical mergers and acquisitions (M&A). This is an encouraging sign of a healthy biopharmaceutical innovation ecosystem.
Innovations Advanced by M&A: A New Medicine Treating Anemia for Patients with Myelofibrosis
GlaxoSmithKline (GSK)’s 2022 acquisition of Sierra Oncology combined Sierra’s specialization in developing targeting therapies for rare blood cancers with GSK’s global scale, regulatory experience and commercialization capabilities — leading to approval of the only first-line medicine to treat myelofibrosis patients who have anemia.